Oncotelic Therapeutics (OTCQB:OTLC) announced it has completed Phase 1 of its trial evaluating OT-101 in combination with IL-2 for advanced metastatic tumors.
According to Oncotelic, this announcement coincides with a presentation delivered by Vuong Trieu, Ph.D., chairman and CEO of Oncotelic, at the 2025 Symposium on World Cancer Research, describing the central role of TGFβ2 in immune suppression across multiple diseases. The presentation also outlined the ongoing development of OT-101 in pancreatic cancer, gliomas, and combination regimens with immunotherapies.
In a statement Dr. Trieu said, “We are thrilled to announce the completion of our Phase 1 study evaluating OT-101 with IL-2, a key milestone that sets the stage for next-generation immunotherapy combinations. Our findings reinforce that OT-101’s specific inhibition of TGFβ2 can significantly enhance the immune response, and we are eager to test these synergies with checkpoint inhibitors and IL-2 to maximize therapeutic potential for patients with hard-to-treat cancers.”
